TLR4 and cancer: MSCs derived extracellular vesicles(reduce angiogenesis, EMT and enhance cancer cell apoptosis)Genetically modified MSC (expressing IFN‐γ,IL‐2, TRAIL)TLR4 agonists reprograms into pro‐inflammatory MSC1